JP2022104747A - 抗ウイルス剤 - Google Patents

抗ウイルス剤 Download PDF

Info

Publication number
JP2022104747A
JP2022104747A JP2020219885A JP2020219885A JP2022104747A JP 2022104747 A JP2022104747 A JP 2022104747A JP 2020219885 A JP2020219885 A JP 2020219885A JP 2020219885 A JP2020219885 A JP 2020219885A JP 2022104747 A JP2022104747 A JP 2022104747A
Authority
JP
Japan
Prior art keywords
virus
therapeutic agent
disease caused
compound
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020219885A
Other languages
English (en)
Japanese (ja)
Inventor
健吉 増富
Kenkichi Masutomi
麻美 安川
Asami Yasukawa
幸一 渡士
Koichi Watashi
光貴 本間
Mitsutaka Honma
俊一 関根
Shunichi Sekine
裕雄 小山
Hiroo Koyama
竹広 深見
Takehiro Fukami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL CANCER CENTER
National Institute of Infectious Diseases
RIKEN Institute of Physical and Chemical Research
Original Assignee
NATIONAL CANCER CENTER
National Institute of Infectious Diseases
RIKEN Institute of Physical and Chemical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CANCER CENTER, National Institute of Infectious Diseases, RIKEN Institute of Physical and Chemical Research filed Critical NATIONAL CANCER CENTER
Priority to JP2020219885A priority Critical patent/JP2022104747A/ja
Priority to PCT/IB2021/062399 priority patent/WO2022144779A1/fr
Publication of JP2022104747A publication Critical patent/JP2022104747A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020219885A 2020-12-29 2020-12-29 抗ウイルス剤 Pending JP2022104747A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020219885A JP2022104747A (ja) 2020-12-29 2020-12-29 抗ウイルス剤
PCT/IB2021/062399 WO2022144779A1 (fr) 2020-12-29 2021-12-28 Dérivés de sulfonamide, compositions les comprenant et utilisations associées contre des virus à arn

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020219885A JP2022104747A (ja) 2020-12-29 2020-12-29 抗ウイルス剤

Publications (1)

Publication Number Publication Date
JP2022104747A true JP2022104747A (ja) 2022-07-11

Family

ID=82259922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020219885A Pending JP2022104747A (ja) 2020-12-29 2020-12-29 抗ウイルス剤

Country Status (2)

Country Link
JP (1) JP2022104747A (fr)
WO (1) WO2022144779A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EA201791982A1 (ru) * 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
KR20190064573A (ko) * 2016-08-18 2019-06-10 인테크린 테라퓨틱스, 아이엔씨. 혈액 암 치료용 PPARγ 작용제

Also Published As

Publication number Publication date
WO2022144779A1 (fr) 2022-07-07

Similar Documents

Publication Publication Date Title
CA3163424A1 (fr) Procedes de traitement d'infections par sras cov-2
CA3139977A1 (fr) Peptidomimetiques pour le traitement d'infections par coronavirus et picornavirus
ES2396595T3 (es) Composición farmacéutica que contiene un derivado de pirazina y método de utilización de un derivado de pirazina en combinación
TW201136945A (en) Purine nucleoside phosphoramidate
JP2018523665A (ja) 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体
JPH10511682A (ja) ジドブジン、１５９２ｕ８９および３ｔｃまたはｆｔｃの相乗的組み合わせ
EA026667B1 (ru) Фармацевтическая композиция для лечения вируса гепатита с
CA2602291A1 (fr) Traitements pour la prevention ou la reduction d'effets indesirables chez un patient ayant une diminution de la fonction ventriculaire gauche
JPWO2007083689A1 (ja) プラスミノーゲンアクチベーターインヒビター−１阻害剤
JP2023516628A (ja) ヌクレオチド系化合物のコロナウイルス感染症の治療での使用
US20190070212A1 (en) Compounds and compositions for the treatment of infections
ES2488821T3 (es) Proceso de preparación de un compuesto antiviral
KR20150005526A (ko) 바이러스 질환을 치료하기 위한 성분 및 방법
JP5976224B2 (ja) ウイルス性疾患を処置するためのヘテロシクリルカルボキサミド
JP2022104747A (ja) 抗ウイルス剤
JP4232866B2 (ja) 細胞障害抑制剤
AU2011223945B2 (en) Compositions and methods for treating viral diseases
CA3220268A1 (fr) Modulation du niveau d'expression d'un gene codant pour une proteine endodesoxyribonuclease apurinique/apyrimidinique par traitement d'un sujet humain avec un nitroxyde
KR20230047396A (ko) 리라글루티드 및 제피티닙의 항바이러스 용도
KR20210129579A (ko) 사스 코로나바이러스 감염증 치료용 약학적 조성물
JP2016540776A (ja) 分枝鎖非環式ヌクレオシドホスホン酸エステルならびにその合成法および使用
CN112022855A (zh) PLpro蛋白抑制剂在治疗或预防新型冠状病毒感染的药物中的应用
US20240091214A1 (en) Lonafarnib for use in the treatment of viral infections
ES2959188T3 (es) Procedimientos de tratamiento de trastornos inflamatorios neurológicos
CA2497410A1 (fr) Hydrazides pyrazole acide carboxylique antibacteriennes